We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
-26.85%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$110M
AUM Growth
-$38.9M
Cap. Flow
+$1.96M
Cap. Flow %
1.77%
Top 10 Hldgs %
96.16%
Holding
13
New
3
Increased
2
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$5.02M
2
CMRX
Chimerix, Inc.
CMRX
+$2.37M
3
INCY icon
Incyte
INCY
+$1.19M
4
DERM
Dermira, Inc.
DERM
+$168K
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$90K

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$5.85M
2
DVAX
Dynavax Technologies
DVAX
+$1.03M

Sector Composition

Rank Sector Weight
1 Healthcare 93.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PDSB icon
1
PDS Biotechnology
PDSB
$38.7M
$21.5M 19.42%
117,243
– –
ARAV
2
DELISTED
Aravive, Inc. Common Stock
ARAV
$16.4M 14.8%
339,871
– –
DMTX
3
DELISTED
Dimension Therapeutics, Inc
DMTX
$16.1M 14.59%
2,059,283
– –
OXFD
4
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$13.7M 12.35%
1,377,497
– –
WVE icon
5
Wave Life Sciences
WVE
$1.12B
$10.9M 9.85%
784,159
– –
DVAX
6
DELISTED
Dynavax Technologies
DVAX
$9.54M 8.64%
496,042
-50,956
-9% -$1.03M
ALDR
7
DELISTED
Alder Biopharmaceuticals
ALDR
$6.07M 5.49%
247,806
-252,592
-50% -$5.85M
SAGE
8
DELISTED
Sage Therapeutics
SAGE
$4.57M 4.14%
+142,570
New +$5.02M
DERM
9
DELISTED
Dermira, Inc.
DERM
$3.8M 3.44%
183,884
+6,862
+4% +$168K
MRNS
10
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.79M 3.43%
176,143
– –
CMRX
11
DELISTED
Chimerix, Inc.
CMRX
$2.98M 2.7%
582,904
+362,371
+164% +$2.37M
INCY icon
12
Incyte
INCY
$23.5B
$1.16M 1.05%
+16,000
New +$1.19M
KPTI icon
13
Karyopharm Therapeutics
KPTI
$168M
$109K 0.1%
+815
New +$90K

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q1 2016 Portfolio in Review

As of Q1 2016, New Leaf Venture Partners held 13 positions worth $110M, down 26% from $149M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

New Leaf Venture Partners's Q1 2016 filing shows 3 new, 2 increased and 2 reduced positions. Its largest new stake was Sage Therapeutics: 142,570 shares worth $4.57M. The largest sale was Alder Biopharmaceuticals, an estimated $5.85M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier.

  • New Leaf Venture Partners's largest Q1 2016 buy was Sage Therapeutics: 142,570 shares worth $4.57M.
  • New Leaf Venture Partners added most to Chimerix, Inc. in Q1 2016, an estimated $2.37M increase.
  • New Leaf Venture Partners's biggest Q1 2016 reduction was Alder Biopharmaceuticals, cutting an estimated $5.85M.
  • New Leaf Venture Partners's ten largest holdings make up 96% of its $110M portfolio in Q1 2016.
  • New Leaf Venture Partners opened 3 new positions and closed 0 in Q1 2016.
  • New Leaf Venture Partners's portfolio value fell 26% quarter-over-quarter to $110M.

Based on New Leaf Venture Partners's 13F filing for Q1 2016, filed 16 May 2016.